Cargando…

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer

The purpose of this study was to investigate the safety, tolerability, and pharmacokinetics of motesanib when combined with docetaxel or paclitaxel in patients with metastatic breast cancer. In this open-label, dose-finding, phase 1b study, patients received motesanib 50 or 125-mg orally once daily...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Boer, Richard H., Kotasek, Dusan, White, Shane, Koczwara, Bogda, Mainwaring, Paul, Chan, Arlene, Melara, Rebeca, Ye, Yining, Adewoye, Adeboye H., Sikorski, Robert, Kaufman, Peter A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2012
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413817/ https://www.ncbi.nlm.nih.gov/pubmed/22872523 http://dx.doi.org/10.1007/s10549-012-2135-0

Ejemplares similares

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study
por: Kotasek, Dusan, et al.
Publicado: (2011)

Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models
por: Coxon, Angela, et al.
Publicado: (2012)

Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience
por: Bass, Michael B., et al.
Publicado: (2014)

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer
por: Burris, Howard, et al.
Publicado: (2011)

Bilateral intermediate uveitis following treatment with paclitaxel in a patient with invasive ductal carcinoma of the breast
por: Kvopka, Michael, et al.
Publicado: (2022)

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors
por: Caenepeel, Sean, et al.
Publicado: (2010)

Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours
por: Price, T J, et al.
Publicado: (2008)

Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study
por: Jain, Minish M., et al.
Publicado: (2016)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

Correction: Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience
Publicado: (2015)

Early cardiac changes following anthracycline chemotherapy in breast cancer: a prospective multi-centre study using advanced cardiac imaging and biochemical markers
por: Grover, Suchi, et al.
Publicado: (2012)

A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors
por: Bauer, Todd M, et al.
Publicado: (2018)

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)
por: Goldstein, Lori J., et al.
Publicado: (2021)

2043: Pharmacokinetic prediction of paclitaxel-induced peripheral neuropathy
por: Hertz, Daniel L., et al.
Publicado: (2018)

nab-Paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis
por: O’Shaughnessy, Joyce, et al.
Publicado: (2013)

Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
por: Martín, M., et al.
Publicado: (2018)

Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
por: Fruehauf, John P., et al.
Publicado: (2018)

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
por: Clemens, Michael R., et al.
Publicado: (2014)

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
por: Kuemmel, Sherko, et al.
Publicado: (2021)

The influence of body mass index on the tolerability and effectiveness of full-weight-based paclitaxel chemotherapy in women with early-stage breast cancer
por: Lin, Lishi, et al.
Publicado: (2022)

Phase II Trial of 5‐Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer
por: Ueda, Hiroto, et al.
Publicado: (2018)

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
por: Martín, Miguel, et al.
Publicado: (2013)

Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer
por: Rajappa, Senthil, et al.
Publicado: (2018)

Ab-initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib
por: Ebadi, Ahmad, et al.
Publicado: (2014)

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer
por: Lacouture, Mario E., et al.
Publicado: (2022)

A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102
por: Gralow, Julie R., et al.
Publicado: (2013)

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
por: Miles, David, et al.
Publicado: (2013)

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
por: Xu, Binghe, et al.
Publicado: (2020)

Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
por: Grierson, Patrick M, et al.
Publicado: (2022)

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
por: William, William N., et al.
Publicado: (2018)

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy
por: Ohno, S., et al.
Publicado: (2013)

Rethinking cancer survivorship: the Prostate Cancer Survivorship Essentials Framework
por: Dunn, Jeff, et al.
Publicado: (2021)

Finding My Way from clinical trial to open access dissemination: comparison of uptake, adherence, and psychosocial outcomes of an online program for cancer-related distress
por: Beatty, Lisa, et al.
Publicado: (2022)

The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine
por: Yahyazadeh-Jabbari, Seyyed-Hossein, et al.
Publicado: (2013)

Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)
por: Hwang, Inhwan, et al.
Publicado: (2023)

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study
por: Xu, Binghe, et al.
Publicado: (2022)

Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer
por: Dassen, Anneriet E, et al.
Publicado: (2016)

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate
por: Sawaki, Akira, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lba1l68fh0kmh0n1ggt4kh4u92